EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intradermal Botulinum Toxin A for Melasma: A Randomized Split‐Face Study Trial and In Vitro Study of Its Antimelanogenic Effect

Wilai Thanasarnaksorn, Thanan Supasiri, Uraiwan Panich, Saowalak Thanachaiphiwat, Nuntida Salakshna

Dermatologic Therapy · 2025-01 · 2025 (1)

DOI: 10.1155/dth/5550483 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatologic Therapy, online erschienen am 21.01.2025. Verfasst von Wilai Thanasarnaksorn und 4 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Melasma is a challenging hyperpigmentation disorder without absolute treatment.

Aims

This study aimed to evaluate the effects of intradermal botulinum toxin A (BoNT‐A) on melasma and the protective effects of BoNT‐A on UVA‐induced melanogenesis in B16F10 melanoma cells. Patients/Methods: This study is a split‐face randomized, double‐blind, placebo‐controlled trial in 12 melasma patients who received intradermal abobotulinumtoxinA injection into melasma lesions. An in vitro study was also conducted in B16F10 melanoma cells treated with different concentrations of BoNT‐A prior to exposure to UVA. Cell viability and cellular melanogenesis were determined.

Results

The adjusted MASI scores on the BoNT‐A side were significantly lower than the control at 3 months after injection, 2.8 versus 4.5 ( p < 0.001), respectively. BoNT‐A injection significantly reduced the MASI score at 2 and 3 months compared with the baseline of 4.1–3.2 (22%) ( p < 0.001) and 2.8 (31.7%) ( p < 0.001), respectively. Melanin content and tyrosinase activity in B16F10 cells with or without UVA irradiation were significantly reduced by treatment with BoNT‐A in a dose‐dependent manner without causing cytotoxicity.

Conclusions

BoNT‐A has a potentially beneficial effect in the treatment of melasma due to its antimelanogenic effect. Trial Registration: Clinical Trial Registry identifier: TCTR20250118001

Zitieren

APA

Thanasarnaksorn, W., Supasiri, T., Panich, U., Thanachaiphiwat, S., & Salakshna, N. (2025). Intradermal Botulinum Toxin A for Melasma: A Randomized Split‐Face Study Trial and In Vitro Study of Its Antimelanogenic Effect. Dermatologic Therapy, 2025(1). https://doi.org/10.1155/dth/5550483

Vancouver

Thanasarnaksorn W, Supasiri T, Panich U, Thanachaiphiwat S, Salakshna N. Intradermal Botulinum Toxin A for Melasma: A Randomized Split‐Face Study Trial and In Vitro Study of Its Antimelanogenic Effect. Dermatologic Therapy. 2025;2025(1). doi:10.1155/dth/5550483

BibTeX
@article{Thanasarnaksorn2025,
  author = {Thanasarnaksorn, Wilai and Supasiri, Thanan and Panich, Uraiwan and Thanachaiphiwat, Saowalak and Salakshna, Nuntida},
  title = {Intradermal Botulinum Toxin A for Melasma: A Randomized Split‐Face Study Trial and In Vitro Study of Its Antimelanogenic Effect},
  journal = {Dermatologic Therapy},
  year = {2025},
  volume = {2025},
  number = {1},
  doi = {10.1155/dth/5550483}
}
Kostenlos starten →